Cambridge Investment Research Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-64,521	Closed	-$245K	–	3828
2025 Q3	$245K	Buy	+64,521	New	+$189K	﹤0.01%	3308
2023 Q2	–	Sell	-11,231	Closed	-$21K	–	3178
2023 Q1	$21K	Hold	11,231	–	–	﹤0.01%	3099
2022 Q4	$20K	Hold	11,231	–	–	﹤0.01%	3041
2022 Q3	$19K	Hold	11,231	–	–	﹤0.01%	3004
2022 Q2	$28K	Hold	11,231	–	–	﹤0.01%	2978
2022 Q1	$31K	Buy	11,231 +200	+2%	+$730	﹤0.01%	3106
2021 Q4	$59K	Buy	+11,031	New	+$77.1K	﹤0.01%	3086

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cambridge Investment Research Advisors's BDTX Position: Q4 2025 in Review

Cambridge Investment Research Advisors sold out of Black Diamond Therapeutics (BDTX) in Q4 2025, closing a stake of 64,521 shares — an estimated $245K sold.

Cambridge Investment Research Advisors first reported a position in BDTX in Q4 2021 and held it in 7 quarters. The position peaked at $245K in Q3 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q4 2025.

Cambridge Investment Research Advisors reported no remaining Black Diamond Therapeutics position as of Q4 2025 after selling out during the quarter.
Cambridge Investment Research Advisors sold 64,521 Black Diamond Therapeutics shares in Q4 2025, an estimated $245K.
Cambridge Investment Research Advisors first reported a position in Black Diamond Therapeutics in Q4 2021 and held it in 7 quarters.
Cambridge Investment Research Advisors's Black Diamond Therapeutics position peaked at $245K in Q3 2025.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2025, filed 5 Feb 2026.